Peanut allergy

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment

Retrieved on: 
Friday, January 8, 2021
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Medical specialties, Clinical medicine, Food allergies, Allergology, Allergen immunotherapy, Immunotherapy, Immune system, Immunology, Peanut allergy, Tree nut allergy, Peanut, Allergy

This clearance is a pivotal regulatory milestone that further supports Camallergys leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy, said Sherden Timmins, Chief Technology Officer.

Key Points: 
  • This clearance is a pivotal regulatory milestone that further supports Camallergys leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy, said Sherden Timmins, Chief Technology Officer.
  • The new manufacturing facility will handle cGMP production of CA002, the Companys proprietary peanut allergy treatment, for planned pivotal clinical trials.
  • Camallergys manufacturing facility is the only European GMP production facility for peanut oral immunotherapy and is scalable for commercial production.
  • Camallergys lead product, CA002, is a novel oral immunotherapy for the treatment of peanut allergy designed to offer bite-proof protection to patients within 14 weeks of therapy.

AllerGenis and Partners Present Positive Precision Medicine Data on Tracking Peanut-Allergy Desensitization Therapy at ACAAI Virtual 2020 Annual Scientific Meeting

Retrieved on: 
Friday, November 13, 2020
Medical specialties, Food allergies, Allergology, Immune system, Immunology, Allergy, Peanut allergy, Desensitization, Immunoglobulin E, Peanut, Tree nut allergy, Tse Wen Chang

Annual incidence of accidental exposures resulting in allergic reactions is more than 10% in peanut-allergic children, highlighting the need for successful desensitization therapies and tools to confirm their effectiveness.

Key Points: 
  • Annual incidence of accidental exposures resulting in allergic reactions is more than 10% in peanut-allergic children, highlighting the need for successful desensitization therapies and tools to confirm their effectiveness.
  • Precision medicine tools are required to monitor response to treatment, as existing tools (sIgE, sIgG4, and components) are insufficient in this context.
  • The results to be presented at ACAAI are based on samples from subjects who participated in the Efficacy and Safety of Viaskin Peanut in Children with Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES) study ( NCT02636699 ).
  • "This type of tracking has the potential to be helpful to emerging therapies."

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

Retrieved on: 
Tuesday, November 10, 2020
Medical specialties, Clinical medicine, Medicine, Food allergies, CAC Mid 60, DBV Technologies, Immune system, Immunology, Peanut allergy, Peanut, DBV, Immunotherapy

An investigational non-invasive, once-daily, epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to activate the immune system.

Key Points: 
  • An investigational non-invasive, once-daily, epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to activate the immune system.
  • DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy.
  • This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of Viaskin Peanut as a treatment for peanut-allergic children.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Peanut Allergy R&D Pipeline Analysis Report, Q4 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 29, 2020
General Health, Pharmaceutical, Health, Medical specialties, Food allergies, Immune system, Immunology, Peanut allergy, Allergy, Peanut, Tree nut allergy, Nima

The "Peanut Allergy R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peanut Allergy R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.
  • The comprehensive report on the indication presents Peanut Allergy disease overview, Peanut Allergy types, Peanut Allergy symptoms, causes, and FDA/EMA approved treatment options.
  • The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Peanut Allergy indication.
  • Further, the presence of large companies and stringent regulations act as barriers for Peanut Allergy pipeline development companies.

Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

Retrieved on: 
Friday, October 16, 2020
Medical specialties, Immunology, Clinical medicine, Food allergies, Peanut allergy, Allergy, Tree nut allergy, Peanut, Anaphylaxis, Immunotherapy, Egg allergy

"We are encouraged by the CHMP opinion, which recommends PALFORZIA as the first and only treatment option in the European Union for patients with peanut allergy and their families," said Andrew Oxtoby, President and Chief Executive Officer of Aimmune Therapeutics.

Key Points: 
  • "We are encouraged by the CHMP opinion, which recommends PALFORZIA as the first and only treatment option in the European Union for patients with peanut allergy and their families," said Andrew Oxtoby, President and Chief Executive Officer of Aimmune Therapeutics.
  • The positive CHMP opinion will be reviewed by the European Commission, and a final decision on PALFORZIA to treat peanut allergy is anticipated in the fourth quarter of 2020.
  • In the US, PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
  • PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy.

FARE Announces SEED to Study and Promote Early Introduction of Allergenic Foods to Prevent Food Allergies

Retrieved on: 
Thursday, October 15, 2020
Medical specialties, Food allergies, Agronomy, Crops, RTT, Immune system, Immunology, Peanut allergy, Food Allergy Research & Education, Allergen, Tree nut allergy, Allergy

SEED is grounded in the success of the Learning Early About Peanut Allergy (LEAP) study that was funded in part by FARE and published in 2015.

Key Points: 
  • SEED is grounded in the success of the Learning Early About Peanut Allergy (LEAP) study that was funded in part by FARE and published in 2015.
  • The SEED study will explore the benefits of early introduction to multiple allergenic foods (specifically peanut, egg, dairy, cashew, soy, almond and sesame) in a more diverse sample of infants.
  • "With the SEED program, FARE continues its pioneering role in supporting early allergen introduction," said Lisa Gable, chief executive officer of FARE.
  • FARE (Food Allergy Research & Education) is the world's leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research.

Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies

Retrieved on: 
Thursday, October 8, 2020
Medical specialties, Clinical medicine, Food allergies, RTT, Immune system, Immunology, Peanut allergy, Tree nut allergy, Immunotherapy, Allergy, Book:Allergies, Kari Nadeau

NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies.

Key Points: 
  • NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies.
  • According to the authors, SLIT has been studied in the treatment of hazelnut, peach, apple, milk and peanut allergies with substantial focus on the treatment of peanut allergy.
  • We are excited about the publication of this comprehensive review of immunotherapy options for food allergies, said William Reisacher, MD, Senior Scientific Advisor, Intrommune Therapeutics.
  • Intrommune, dedicated to improving and protecting the lives of people with food allergy, is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies.

Intrommune Therapeutics Featured at Upcoming Investor Conferences

Retrieved on: 
Monday, October 5, 2020
Peanut allergy

Intrommune Therapeutics CEO, Michael Nelson , will present at all three of these virtual conferences.

Key Points: 
  • Intrommune Therapeutics CEO, Michael Nelson , will present at all three of these virtual conferences.
  • As we continue to drive our lead compound through the development process, we are committed to keeping the investment and scientific communities updated on our progress, said Michael Nelson, CEO, Intrommune Therapeutics.
  • For more information about Intrommune and its events calendar, please visit: http://www.intrommune.com/upcoming-events
    Intrommunes lead product, INT301, is being developed for the treatment of peanut allergies.
  • For more information on Intrommune Therapeutics, please visit http://www.intrommune.com .

Half of People with Food Allergies Report At Least One Allergic Reaction Each Year

Retrieved on: 
Monday, September 21, 2020
Medical specialties, Food allergies, RTT, Immune system, Immunology, Allergology, Food Allergy Research & Education, Allergy, Allergen, Peanut allergy, Fruit allergy

The study explores the frequency of food-related reactions and the motivation for intentional exposure to a known food allergen and found that more than 50 percent of those with food allergies report having at least one food-related allergic reaction per year.

Key Points: 
  • The study explores the frequency of food-related reactions and the motivation for intentional exposure to a known food allergen and found that more than 50 percent of those with food allergies report having at least one food-related allergic reaction per year.
  • The primary data source for this study was FARE's Patient Registry, a national online repository of data collected from participants with food allergy.
  • "Very little data exists on the frequency and context of food-related allergic reactions and this study shows us that more research is needed."
  • To learn more about the FARE Patient Registry, please visit: https://www.foodallergypatientregistry.org/
    FARE (Food Allergy Research & Education) is the world's leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research.

New Clinical Trials and Acquisitions Announced in the Allergy Drugs Sector

Retrieved on: 
Tuesday, September 15, 2020
Medical specialties, Clinical medicine, Food allergies, Arachis, RTT, Immune system, Immunology, Peanut, Allergy, Niacin, Peanut allergy

Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio.

Key Points: 
  • Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes's Palforzia to its portfolio.
  • Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers.
  • The drug is derived from peanut powder and works by exposing patients to escalating doses mixed with other foods.
  • Aquestive Therapeutics recently launched a phase 1 clinical trial of an epinephrine film that dissolves under the tongue.